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1. Introduction 
Recent studies have provided evidence that GIP 
may play an important regulatory role in the modula- 
tion of the binding affinity of some ol,-adrenergic 
receptors [l-5]. However, this effect of GTP, which 
seems analogous to its now well established action on 
agonist-binding to the P-adrenergic receptors of dif- 
ferent cells including adipocytes [6-l 01, has been so 
far shown to apply to the ol,-adrenergic receptors of 
rather limited examples to allow generalization to all 
cellular systems involving a,-adrenergic receptors. 
Recent reports from this laboratory [ 1 l-121 and 
others [ 131 have demonstrated by direct binding 
experiments the existence of cw-adrenergic receptors in 
hamster fat cells. Since these studies have shown that 
these receptors were predominantly constituted by the 
cw,-adrenergic subtype [12,13], the aim of the present 
investigation was to determine whether GTP may also 
specifically regulate the affinity of these receptors 
towards their agonists. This was achieved by studying 
the influence of the non-hydrolyzable analog of GTP, 
guanosine 5’{p;u-imido)triphosphate (Gpp(NH)p) on 
the binding of the a-antagonist [3H]dihydroergocryp- 
tine and of the a-agonist [3H]norepinephrine as well 
as on the displacement of [ 3H] dihydroergocryptine 
by various a-agonists and antagonists. This report 
shows that, Gpp(NH)p does not affect the binding of 
the a-antagonist [ 3H] dihydroergocryptine nor its dis- 
placement by the a-antagonists phentolamine and 
yohimbine. However, Gpp(NH)p severely decreases 
the overall binding affinity of the a-adrenergic recep- 
tors of hamster adipocytes for the a-agonists (-)epi- 
nephrine and [jH]norepinephrine and for the c+selec- 
tive agonist clonidine ,an effect which appears to result 
from the conversion of the high affinity state of the 
ElsevieriNorth-Holland Biomedical Press 
adipocyte cu,-receptor for agonists into the low affinity 
one. 
2. Material and methods 
Binding assays were performed on crude adipocyte 
membranes prepared from isolated hamster adipocytes 
and then thoroughly washed (to reduce endogenous 
GTP) as described in detail elsewhere [ 111. When 
[ 3H] norepinephrine binding was studied, membranes 
(150-200 pg of protein) were incubated in Tris-HCl 
(50 mM), MgCl* (5 mM), ascorbate (0.8 mM), pyro- 
catechol(1 mM), (+)-propranolol (10 PM) (pH 7.4 at 
25°C) to suppress binding to the P-receptors and with 
various concentrations of [3H]norepinephrine (spec. 
activity 38 Ci mmol-‘, Radiochemical Centre, 
Amersham), in a total volume of 120 /_d. Incubations 
were performed for 30 min at 25°C (optimal condi- 
tions of binding) [ 141 and were terminated by adding 
5 ml incubation buffer, followed by a rapid vacuum 
filtration of the suspension through Whatman GF/C 
glass fiber filters. Filters were washed with 10 ml of 
buffer, were dried, were added to scintillation cocktail 
(PCS, Amersham) and were counted. Specific binding 
defined as binding displaceable by 10 PM phentol- 
amine (Ciba) averaged 55-70s of total binding at 
40 nM t3H] norepinephrine. 
When [ 3H]dihydroergocryptine binding was stud- 
ied, membranes (200 pg of protein) were incubated 
with [ 3H] dihydroergocryptine (spec. act. 22 Ci 
mmol-‘, Radiochemical Centre, Amersham) (usually 
9-10 nM) in Tris-HCl(50 mM), MgClz (10 mM) 
buffer (pH 7.4 at 37°C) in a total volume of 150 ~1. 
After 10 min, incubations were terminated and radio- 
activity bound to the filter was determined as pre- 
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viously described [ 1 I]. Specific binding (binding dis- 
placeable by 10 /IM phentolamine) was 75% of total 
binding at 10 MM [ 3H] dihydroergocryptine. Origin of 
the chemicals used are described elsewhere [ 11,12]. 
3. Results and discussion 
As shown in fig.lA, the binding of [3H]dihydro- 
ergocryptine was unaffected by the presence of 
100 PM Gpp(NH)p (Boehringer, Mannheim), a con- 
centration which altered neither the total nor the 
non-specific binding of [ 3H] dihydroergocryptine. 
Competition curves of phentolamine (a mixed a,- and 
01~ - antagonist) [ 151 and of yohimbine (a preferential 
az-antagonist) [16] in displacing [3H]dihydroergo- 
cryptine were also unaltered by the addition of 
Gpp(NH)p (fig .l B). 
Fig.2A shows the effects of Gpp(NH)p on the abil- 
ity of (-)-epinephrine to displace [‘HI dihydroergo- 
cryptine. As can be seen, the competition curve in the 
absence of the nucleotide was biphasic (log-logit trans- 
formation of the data yielding a slope value nlj = 
0.56), suggesting the existence of two affinity states 
of the adipocyte cr-receptor for (-)epinephrine with 
respective apparent EC’50 values of 80-l 00 nM and 
3500-4000 nM. This is consistent with previous data 
from this laboratory [ 141 and from the present study 
(see fig.2B) showing by direct equilibrium binding 
studies the presence of two different binding compo- 
nents for [3H]norepinephrine in hamster adipocyte 
membranes. Contrasting with the failure of Gpp(NH)p 
to alter [ 3H] dihydroergocryptine, phentolamine and 
yohimbine binding, this nucleotide markedly affected 
the ability of (-)epinephrine to displace [3H] dihy- 
droergocryptine. In fact, the (-)epinephrine compe- 
tition curve was steeper and shifted to the right in the 
presence of Gpp(NH)p. Log-logit transformation of 
these data yielded a slope nH = 0.97 which is consis- 
tent with displacement at a single class of binding sites 
and an ECso value of 2500 nM, which is close to the 
ECSo value found in the absence of Gpp(NH)p for the 
sites displaced with low affinity by (-)-epinephrine. 
This suggests that the guanine nucleotide may induce 
a conversion of the high affinity state of the cy-recep- 
tor for catecholamine into the low affinity one. Con- 
sistent with this hypothesis is the fact that in the pres- 
ence of Gpp(NH)p, no specific binding of [3H]norep- 
inephrine could be detected at concentrations less than 
20 nM (fig.2B) an effect which reflects a selective 
Fig.1. Influence of Gpp(NH)p on the specific binding of oi-adrenergic antagonists to the ol-adrenergic receptors of hamster adi- 
pocyte membranes. A. Concentration dependence curve for specific binding of [ “Hldihydroergocryptine. Membranes were incu- 
bated at 37OC with various concentrations of [3H]dihyd~oergocryptine, in the absence or presence of 100 /IM Gpp(NH)p. After 
10 mm, the amount ofradioligand specifically bound was determined. Each point represents the mean of triplicate determinations 
from one experiment. B. Displacement of [ “tf]dihydroergocryptine specifically bound to hamster adipocyte membranes by phen- 
tolamine and yohimbine. Membranes were incubated at 37°C with 9 nM [ ‘Hldihydroergocryptine and various concentrations of 
phentolamine and yohimbme, in the absence or presence of 100 PM Gpp(NH)p. After 10 mm, the amount of radioligand remain- 
ing specifically bound was determined. Results are expressed as percent of [ ‘Hldihydroergocryptine specifically bound in the 
absence of phentolamine or yohimbine. Each point is the mean of two different experiments performed in triplicate. 
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Fig.2. Influence of Gpp(NH)p on the specific binding of catecholamines to the ol-adrenergic receptors of hamster adipocyte mem- 
branes. A. Displacement of [ ‘Hldihydroergocryptine specifically bound to hamster adipocyte membranes by (-)epinephrine. 
Experimental conditions are as described under fig.lB. Each point is the mean of three different experiments performed in tripli- 
cate and the vertical lines represent 2 S.E.M. B. Concentration dependence curve for specific binding of [ ‘Hlnorepinephrine to 
hamster adipocyte membranes. Membranes were incubated with increasing concentrations of [ 3H]norepinephrine at 25°C for 
30 mm in the absence (total binding) or presence of 10 PM phentolamine (non-specific binding), under the conditions described 
in the text. Gpp(NH)p (100 PM) was present in half of the assays. Data points represent the mean of triplicate determinations 
from one representative experiment and the vertical lines 2 S.E.M. 
abolition of the binding of [3H]norepinephrine to its 
high affinity binding component. 
As the @-receptor population of hamster fat cells is 
almost completely constituted by the a,-adrenergic 
Fig.3. Influences of Gpp(NH)p on the displacement of 
[ 3H]dihydroergocryptine specifically bound to adipocyte 
membranes by clonidine. Experimental conditions were the 
same as in fig.2A, except that clonidine was used instead of 
(oepinephrine. Each point is the mean of three different 
experiments performed in triplicate and the vertical lines 
represent 2 S.E.M. 
receptor subtype [12,13], it seemed likely that the 
effects of Gpp(NH)p on catecholamine binding 
resulted from an effect of the guanine nucleotide on 
agonist-binding to the cx,-receptor subtype. This 
hypothesis was investigated by studying the influence 
of Gpp(NH)p on the competition curve of the selective 
a,-agonist clonidine [ 171 in displacing [3H]dihydro- 
ergocryptine. As shown in fig.3, the competition curve 
in the absence of the nucleotide was shallow yielding 
logit slope value nH = 0.66 and ECsO value of 
70-90 nM. In the presence of Gpp(NH)p, the cloni- 
dine competition curve was steeper (nH = 0.94) and 
shifted to the right resulting in a 5-6-fold decrease in 
the receptor-binding affinity for this a,-agonist. These 
data are thus consistent with the hypothesis that the 
a,-adrenergic receptor of hamster fat cells has one 
affinity state for a-antagonists, such as phentolamine 
and yohimbine, whether guanine nucleotides are 
present or not, whereas it has two different affinity 
states for cY,-agonists uch as clonidine, the propor- 
tion of which is dependent on the presence of these 
nucleotides: in fact, in the presence of Gpp(NH)p, 
cu,-agonists appear to bind to a homogeneous and low 
affinity state of the receptor, whereas in the absence 
of Gpp(NH)p, these agonists bind to both the high 
and low affinity states of the a,-receptor subtype. 
These experiments thus suggest hat in hamster fat 
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cells, as in platelets [2,4], uterus [4] and brain [l], 
GTP plays an important role in the regulation of ago- 
nist binding to the ol,-adrenergic receptor, by convert- 
ing the high affinity state into the low affinity form 
of the receptor. Such a regulatory role of GTP has 
already been postulated for adenylate cyclase-coupled 
receptors in which agonist binding results not only in 
cyclase activation (for instance, /3-adrenergic receptors 
of different cells including adipocytes) [6-lo], but 
also in cyclase inhibition [2 ,181. This is especially the 
case in hamster fat cells, in which Aktories et al. [ 191 
have recently shown the direct inhibition of adenylate 
cyclase by a-adrenergic agonists. As in the case of 
human platelets [ 161, this inhibition of adipocyte 
adenylate cyclase appears to be mediated by the oZ- 
adrenergic receptor subtype [13,14,20,21]. It seems 
thus possible that the a,-receptors of the fat cell inter- 
act, like the P-receptors, with a membrane-bound 
nucleotide-regulatory protein [22],and that thisinter- 
action is important in the guanine nucleotide-mediated 
modulation of agonist affinity states. In analogy with 
the /3-adrenergic receptors of rat adipocytes [g-lo], 
the existence of such an interaction would also sug- 
gest the possibility that the cY,-adrenergic receptors of 
hamster fat cells may be desensitizable by catechola- 
mines. 
In conclusion, this study shows that the a,-receptor 
of hamster adipocyte is, beside the rather few systems 
so far studied, an additional example of a post-synap- 
tic and inhibitory adenylate cyclasecoupled oc,-recep- 
tor in which agonist-binding is regulated by guanine 
nucleotides. Examination of other examples of a*- 
receptors will determine whether this nucleotide regu- 
lation can be generalized to other tissues and species. 
This might be of particular interest for human adipose 
tissue, in which the a-adrenergic receptors have been 
recently recognized as belonging to the cY,-subtype 
[23] and in which catecholamines appear to be the 
only hormones exerting a physiological role in the 
regulation of lipolysis [24]. 
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